Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis
BACKGROUND: The origin of infertility in patients with endometriosis without tubal occlusion has not yet been clearly defined. Several reports show an abnormal pituitary–ovarian axis in this group of patients. Moreover, prolactin (PRL) and growth hormone (GH) secretion is closely related to reproduc...
Gespeichert in:
| Veröffentlicht in: | Human reproduction (Oxford) 2002-04, Vol.17 (4), p.960-965 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 965 |
|---|---|
| container_issue | 4 |
| container_start_page | 960 |
| container_title | Human reproduction (Oxford) |
| container_volume | 17 |
| creator | Cunha-Filho, J.S. Gross, J.L. Lemos, N.A. Dias, E.C. Vettori, D. Souza, C.A. Passos, E.P. |
| description | BACKGROUND: The origin of infertility in patients with endometriosis without tubal occlusion has not yet been clearly defined. Several reports show an abnormal pituitary–ovarian axis in this group of patients. Moreover, prolactin (PRL) and growth hormone (GH) secretion is closely related to reproductive status. This study aimed to evaluate PRL and GH secretion after metoclopramide and thyrotrophin-releasing hormone (TRH) infusion in infertile patients with minimal/mild endometriosis. METHODS: A total of 64 women participated in the study: 33 fertile patients without endometriosis; 10 fertile patients with minimal/mild endometriosis; and 21 infertile patients with minimal/mild endometriosis. TRH or metoclopramide was administered randomly in two sequential menstrual cycles (cycle days 3–5). Serum PRL and GH secretion before and after dopaminergic type 2 (DA2) receptor blockade and TRH were compared. RESULTS: Higher serum PRL levels were observed in patients with endometriosis at baseline and after 15 and 30 min of TRH administration. Also, infertile patients with endometriosis had lower serum estradiol levels than fertile patients. Moreover, the dopaminergic blockade did not result in abnormal PRL or GH secretion. CONCLUSIONS: Decreased serum estradiol levels and altered PRL secretion after TRH administration in infertile patients with minimal/mild endometriosis are related to ovulatory dysfunction and infertility in this group of patients without tubal occlusion. |
| doi_str_mv | 10.1093/humrep/17.4.960 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71560005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/humrep/17.4.960</oup_id><sourcerecordid>71560005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-cae8efd07fe4f5b7ac38d9bb69449132394ae76266e18d8f1054afc9dd2147223</originalsourceid><addsrcrecordid>eNqN0ctu1DAUBuAIgei0sGaHsgEBUmbsOHHiZVUKA6oElUBU3ViOfTIxdexgOyp9JZ4SDxm1W1Y-kr9zkf4se4HRGiNGNsM8epg2uFlXa0bRo2yFK4qKktTocbZCJW0LjCk-yo5D-IlQKlv6NDvCmJU1YWiV_fnqnREyapsLq_Kdd7dxyAfnR2chDyA9RO3SZx_B53G48y56Nw3aFh4MiKDt7p5r28_hn06jlJvEqC34nZb5m_en5du8M07eCLWHews-agP5JKIGG0N-q9Pq1KJHYTajNioHq9wI0WsXdHiWPemFCfD88J5k3z-cfzvbFhdfPn46O70oJGE0FlJAC71CTQ9VX3eNkKRVrOsoqyqGSUlYJaChJaWAW9X2GNWV6CVTqsRVU5bkJHu9zJ28-zVDiHzUQYIxwoKbA29wTRFCdYKbBUrvQvDQ88mn2_0dx4jv4-FLPBw3vOIpntTx8jB67kZQD_6QRwKvDkAEKUzvhZU6PDiSNld4f-O7xbl5-o-txYJ1iPD7ngt_w2lDmppvr675Nbrafv5RX_JL8hclWLwt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71560005</pqid></control><display><type>article</type><title>Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis</title><source>MEDLINE</source><source>Oxford University Press Journals Current</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Cunha-Filho, J.S. ; Gross, J.L. ; Lemos, N.A. ; Dias, E.C. ; Vettori, D. ; Souza, C.A. ; Passos, E.P.</creator><creatorcontrib>Cunha-Filho, J.S. ; Gross, J.L. ; Lemos, N.A. ; Dias, E.C. ; Vettori, D. ; Souza, C.A. ; Passos, E.P.</creatorcontrib><description>BACKGROUND: The origin of infertility in patients with endometriosis without tubal occlusion has not yet been clearly defined. Several reports show an abnormal pituitary–ovarian axis in this group of patients. Moreover, prolactin (PRL) and growth hormone (GH) secretion is closely related to reproductive status. This study aimed to evaluate PRL and GH secretion after metoclopramide and thyrotrophin-releasing hormone (TRH) infusion in infertile patients with minimal/mild endometriosis. METHODS: A total of 64 women participated in the study: 33 fertile patients without endometriosis; 10 fertile patients with minimal/mild endometriosis; and 21 infertile patients with minimal/mild endometriosis. TRH or metoclopramide was administered randomly in two sequential menstrual cycles (cycle days 3–5). Serum PRL and GH secretion before and after dopaminergic type 2 (DA2) receptor blockade and TRH were compared. RESULTS: Higher serum PRL levels were observed in patients with endometriosis at baseline and after 15 and 30 min of TRH administration. Also, infertile patients with endometriosis had lower serum estradiol levels than fertile patients. Moreover, the dopaminergic blockade did not result in abnormal PRL or GH secretion. CONCLUSIONS: Decreased serum estradiol levels and altered PRL secretion after TRH administration in infertile patients with minimal/mild endometriosis are related to ovulatory dysfunction and infertility in this group of patients without tubal occlusion.</description><identifier>ISSN: 0268-1161</identifier><identifier>ISSN: 1460-2350</identifier><identifier>EISSN: 1460-2350</identifier><identifier>DOI: 10.1093/humrep/17.4.960</identifier><identifier>PMID: 11925390</identifier><identifier>CODEN: HUREEE</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Biological and medical sciences ; Case-Control Studies ; Dopamine Antagonists - therapeutic use ; Dopamine D2 Receptor Antagonists ; endometriosis ; Endometriosis - complications ; Endometriosis - drug therapy ; Estradiol - blood ; Female ; Female genital diseases ; GH secretion ; Gynecology. Andrology. Obstetrics ; Human Growth Hormone - metabolism ; Humans ; infertility ; Infertility, Female - etiology ; Infertility, Female - metabolism ; Medical sciences ; Metoclopramide - therapeutic use ; Non tumoral diseases ; Prolactin - metabolism ; prolactin secretion ; Severity of Illness Index ; Thyrotropin-Releasing Hormone - administration & dosage ; Thyrotropin-Releasing Hormone - therapeutic use</subject><ispartof>Human reproduction (Oxford), 2002-04, Vol.17 (4), p.960-965</ispartof><rights>European Society of Human Reproduction and Embryology 2002</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-cae8efd07fe4f5b7ac38d9bb69449132394ae76266e18d8f1054afc9dd2147223</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1580,27906,27907</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13600412$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11925390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cunha-Filho, J.S.</creatorcontrib><creatorcontrib>Gross, J.L.</creatorcontrib><creatorcontrib>Lemos, N.A.</creatorcontrib><creatorcontrib>Dias, E.C.</creatorcontrib><creatorcontrib>Vettori, D.</creatorcontrib><creatorcontrib>Souza, C.A.</creatorcontrib><creatorcontrib>Passos, E.P.</creatorcontrib><title>Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis</title><title>Human reproduction (Oxford)</title><addtitle>Hum. Reprod</addtitle><addtitle>Hum. Reprod</addtitle><description>BACKGROUND: The origin of infertility in patients with endometriosis without tubal occlusion has not yet been clearly defined. Several reports show an abnormal pituitary–ovarian axis in this group of patients. Moreover, prolactin (PRL) and growth hormone (GH) secretion is closely related to reproductive status. This study aimed to evaluate PRL and GH secretion after metoclopramide and thyrotrophin-releasing hormone (TRH) infusion in infertile patients with minimal/mild endometriosis. METHODS: A total of 64 women participated in the study: 33 fertile patients without endometriosis; 10 fertile patients with minimal/mild endometriosis; and 21 infertile patients with minimal/mild endometriosis. TRH or metoclopramide was administered randomly in two sequential menstrual cycles (cycle days 3–5). Serum PRL and GH secretion before and after dopaminergic type 2 (DA2) receptor blockade and TRH were compared. RESULTS: Higher serum PRL levels were observed in patients with endometriosis at baseline and after 15 and 30 min of TRH administration. Also, infertile patients with endometriosis had lower serum estradiol levels than fertile patients. Moreover, the dopaminergic blockade did not result in abnormal PRL or GH secretion. CONCLUSIONS: Decreased serum estradiol levels and altered PRL secretion after TRH administration in infertile patients with minimal/mild endometriosis are related to ovulatory dysfunction and infertility in this group of patients without tubal occlusion.</description><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Dopamine Antagonists - therapeutic use</subject><subject>Dopamine D2 Receptor Antagonists</subject><subject>endometriosis</subject><subject>Endometriosis - complications</subject><subject>Endometriosis - drug therapy</subject><subject>Estradiol - blood</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>GH secretion</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Human Growth Hormone - metabolism</subject><subject>Humans</subject><subject>infertility</subject><subject>Infertility, Female - etiology</subject><subject>Infertility, Female - metabolism</subject><subject>Medical sciences</subject><subject>Metoclopramide - therapeutic use</subject><subject>Non tumoral diseases</subject><subject>Prolactin - metabolism</subject><subject>prolactin secretion</subject><subject>Severity of Illness Index</subject><subject>Thyrotropin-Releasing Hormone - administration & dosage</subject><subject>Thyrotropin-Releasing Hormone - therapeutic use</subject><issn>0268-1161</issn><issn>1460-2350</issn><issn>1460-2350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0ctu1DAUBuAIgei0sGaHsgEBUmbsOHHiZVUKA6oElUBU3ViOfTIxdexgOyp9JZ4SDxm1W1Y-kr9zkf4se4HRGiNGNsM8epg2uFlXa0bRo2yFK4qKktTocbZCJW0LjCk-yo5D-IlQKlv6NDvCmJU1YWiV_fnqnREyapsLq_Kdd7dxyAfnR2chDyA9RO3SZx_B53G48y56Nw3aFh4MiKDt7p5r28_hn06jlJvEqC34nZb5m_en5du8M07eCLWHews-agP5JKIGG0N-q9Pq1KJHYTajNioHq9wI0WsXdHiWPemFCfD88J5k3z-cfzvbFhdfPn46O70oJGE0FlJAC71CTQ9VX3eNkKRVrOsoqyqGSUlYJaChJaWAW9X2GNWV6CVTqsRVU5bkJHu9zJ28-zVDiHzUQYIxwoKbA29wTRFCdYKbBUrvQvDQ88mn2_0dx4jv4-FLPBw3vOIpntTx8jB67kZQD_6QRwKvDkAEKUzvhZU6PDiSNld4f-O7xbl5-o-txYJ1iPD7ngt_w2lDmppvr675Nbrafv5RX_JL8hclWLwt</recordid><startdate>20020401</startdate><enddate>20020401</enddate><creator>Cunha-Filho, J.S.</creator><creator>Gross, J.L.</creator><creator>Lemos, N.A.</creator><creator>Dias, E.C.</creator><creator>Vettori, D.</creator><creator>Souza, C.A.</creator><creator>Passos, E.P.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020401</creationdate><title>Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis</title><author>Cunha-Filho, J.S. ; Gross, J.L. ; Lemos, N.A. ; Dias, E.C. ; Vettori, D. ; Souza, C.A. ; Passos, E.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-cae8efd07fe4f5b7ac38d9bb69449132394ae76266e18d8f1054afc9dd2147223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Dopamine Antagonists - therapeutic use</topic><topic>Dopamine D2 Receptor Antagonists</topic><topic>endometriosis</topic><topic>Endometriosis - complications</topic><topic>Endometriosis - drug therapy</topic><topic>Estradiol - blood</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>GH secretion</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Human Growth Hormone - metabolism</topic><topic>Humans</topic><topic>infertility</topic><topic>Infertility, Female - etiology</topic><topic>Infertility, Female - metabolism</topic><topic>Medical sciences</topic><topic>Metoclopramide - therapeutic use</topic><topic>Non tumoral diseases</topic><topic>Prolactin - metabolism</topic><topic>prolactin secretion</topic><topic>Severity of Illness Index</topic><topic>Thyrotropin-Releasing Hormone - administration & dosage</topic><topic>Thyrotropin-Releasing Hormone - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cunha-Filho, J.S.</creatorcontrib><creatorcontrib>Gross, J.L.</creatorcontrib><creatorcontrib>Lemos, N.A.</creatorcontrib><creatorcontrib>Dias, E.C.</creatorcontrib><creatorcontrib>Vettori, D.</creatorcontrib><creatorcontrib>Souza, C.A.</creatorcontrib><creatorcontrib>Passos, E.P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Human reproduction (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cunha-Filho, J.S.</au><au>Gross, J.L.</au><au>Lemos, N.A.</au><au>Dias, E.C.</au><au>Vettori, D.</au><au>Souza, C.A.</au><au>Passos, E.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis</atitle><jtitle>Human reproduction (Oxford)</jtitle><stitle>Hum. Reprod</stitle><addtitle>Hum. Reprod</addtitle><date>2002-04-01</date><risdate>2002</risdate><volume>17</volume><issue>4</issue><spage>960</spage><epage>965</epage><pages>960-965</pages><issn>0268-1161</issn><issn>1460-2350</issn><eissn>1460-2350</eissn><coden>HUREEE</coden><abstract>BACKGROUND: The origin of infertility in patients with endometriosis without tubal occlusion has not yet been clearly defined. Several reports show an abnormal pituitary–ovarian axis in this group of patients. Moreover, prolactin (PRL) and growth hormone (GH) secretion is closely related to reproductive status. This study aimed to evaluate PRL and GH secretion after metoclopramide and thyrotrophin-releasing hormone (TRH) infusion in infertile patients with minimal/mild endometriosis. METHODS: A total of 64 women participated in the study: 33 fertile patients without endometriosis; 10 fertile patients with minimal/mild endometriosis; and 21 infertile patients with minimal/mild endometriosis. TRH or metoclopramide was administered randomly in two sequential menstrual cycles (cycle days 3–5). Serum PRL and GH secretion before and after dopaminergic type 2 (DA2) receptor blockade and TRH were compared. RESULTS: Higher serum PRL levels were observed in patients with endometriosis at baseline and after 15 and 30 min of TRH administration. Also, infertile patients with endometriosis had lower serum estradiol levels than fertile patients. Moreover, the dopaminergic blockade did not result in abnormal PRL or GH secretion. CONCLUSIONS: Decreased serum estradiol levels and altered PRL secretion after TRH administration in infertile patients with minimal/mild endometriosis are related to ovulatory dysfunction and infertility in this group of patients without tubal occlusion.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>11925390</pmid><doi>10.1093/humrep/17.4.960</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-1161 |
| ispartof | Human reproduction (Oxford), 2002-04, Vol.17 (4), p.960-965 |
| issn | 0268-1161 1460-2350 1460-2350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71560005 |
| source | MEDLINE; Oxford University Press Journals Current; EZB-FREE-00999 freely available EZB journals |
| subjects | Biological and medical sciences Case-Control Studies Dopamine Antagonists - therapeutic use Dopamine D2 Receptor Antagonists endometriosis Endometriosis - complications Endometriosis - drug therapy Estradiol - blood Female Female genital diseases GH secretion Gynecology. Andrology. Obstetrics Human Growth Hormone - metabolism Humans infertility Infertility, Female - etiology Infertility, Female - metabolism Medical sciences Metoclopramide - therapeutic use Non tumoral diseases Prolactin - metabolism prolactin secretion Severity of Illness Index Thyrotropin-Releasing Hormone - administration & dosage Thyrotropin-Releasing Hormone - therapeutic use |
| title | Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T09%3A56%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolactin%20and%20growth%20hormone%20secretion%20after%20thyrotrophin-releasing%20hormone%20infusion%20and%20dopaminergic%20(DA2)%20blockade%20in%20infertile%20patients%20with%20minimal/mild%20endometriosis&rft.jtitle=Human%20reproduction%20(Oxford)&rft.au=Cunha-Filho,%20J.S.&rft.date=2002-04-01&rft.volume=17&rft.issue=4&rft.spage=960&rft.epage=965&rft.pages=960-965&rft.issn=0268-1161&rft.eissn=1460-2350&rft.coden=HUREEE&rft_id=info:doi/10.1093/humrep/17.4.960&rft_dat=%3Cproquest_cross%3E71560005%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71560005&rft_id=info:pmid/11925390&rft_oup_id=10.1093/humrep/17.4.960&rfr_iscdi=true |